{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:06:25Z","timestamp":1791633985704,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01408-w","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:54:57Z","timestamp":1769612097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selective blockade of latent TGF-\u03b21 activation suppresses tissue fibrosis with good safety"],"prefix":"10.1038","volume":"6","author":[{"given":"Masakazu","family":"Kanamori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-0260","authenticated-orcid":false,"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Xing\u2019er","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1894-2285","authenticated-orcid":false,"given":"Kenji","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Wan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chai Ling","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiri","family":"Shida-Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisako","family":"Kanamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kayukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-7936","authenticated-orcid":false,"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-8220","authenticated-orcid":false,"given":"Tomoyuki","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-1385","authenticated-orcid":false,"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","volume":"342","author":"GC Blobe","year":"2000","unstructured":"Blobe, G. C., Schiemann, W. P. & Lodish, H. F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342, 1350\u20131358 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1408_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","volume":"10","author":"GA Michelotti","year":"2013","unstructured":"Michelotti, G. A., Machado, M. V. & Diehl, A. M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10, 656\u2013665 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1408_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrneph.2015.215","volume":"12","author":"D Zhou","year":"2016","unstructured":"Zhou, D. & Liu, Y. Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis. Nat. Rev. Nephrol. 12, 68\u201370 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1408_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188356","volume":"1873","author":"B Piersma","year":"2020","unstructured":"Piersma, B., Hayward, M. K. & Weaver, V. M. Fibrosis and cancer: A strained relationship. Biochim Biophys. Acta Rev. Cancer 1873, 188356 (2020).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"1408_CR5","doi-asserted-by":"publisher","first-page":"20180214","DOI":"10.1098\/rstb.2018.0214","volume":"374","author":"VG Martinez","year":"2019","unstructured":"Martinez, V. G., Park, D. & Acton, S. E. Immunotherapy: Breaching the barriers for cancer treatment. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374, 20180214 (2019).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1408_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","volume":"11","author":"SW Chung","year":"2021","unstructured":"Chung, S. W., Xie, Y. & Suk, J. S. Overcoming physical stromal barriers to cancer immunotherapy. Drug Deliv. Transl. Res 11, 2430\u20132447 (2021).","journal-title":"Drug Deliv. Transl. Res"},{"key":"1408_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: The master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1408_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1083\/jcb.200704042","volume":"179","author":"PJ Wipff","year":"2007","unstructured":"Wipff, P. J., Rifkin, D. B., Meister, J. J. & Hinz, B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179, 1311\u20131323 (2007).","journal-title":"J. Cell Biol."},{"key":"1408_CR9","volume":"2012","author":"JJ Lebrun","year":"2012","unstructured":"Lebrun, J. J. The dual role of TGFbeta in human cancer: from tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 381428 (2012).","journal-title":"ISRN Mol. Biol."},{"key":"1408_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1408_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGFbeta biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1408_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13, 788\u2013799 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1408_CR13","doi-asserted-by":"publisher","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","volume":"9","author":"S Sanjabi","year":"2017","unstructured":"Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-beta: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1408_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"1408_CR15","unstructured":"Stauber, A. J., Credille, K. M., Truex, L. L., Ehlhardt, W. J. & Young, J. K. Nonclinical safety evaluation of a transforming growth factor \u03b2 receptor i kinase inhibitor in fischer 344 rats and beagle dogs. J. Clin. Toxicol. 4, 1\u201310 (2014)."},{"key":"1408_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","volume":"175","author":"MS Mitra","year":"2020","unstructured":"Mitra, M. S. et al. A potent pan-TGFbeta neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol. Sci. 175, 24\u201334 (2020).","journal-title":"Toxicol. Sci."},{"key":"1408_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","volume":"64","author":"ME Lacouture","year":"2015","unstructured":"Lacouture, M. E. et al. Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64, 437\u2013446 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"1408_CR18","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1200\/JCO.2022.40.16_suppl.2524","volume":"40","author":"D Robbrecht","year":"2022","unstructured":"Robbrecht, D. et al. Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGF\u03b2 inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors. J. Clin. Oncol. 40, 2524\u20132524 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1408_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8456","volume":"12","author":"CJ Martin","year":"2020","unstructured":"Martin, C. J. et al. Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci. Transl. Med 12, eaay8456 (2020).","journal-title":"Sci. Transl. Med"},{"key":"1408_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1046\/j.1523-1755.2003.00162.x","volume":"64","author":"L Yu","year":"2003","unstructured":"Yu, L., Border, W. A., Huang, Y. & Noble, N. A. TGF-beta isoforms in renal fibrogenesis. Kidney Int 64, 844\u2013856 (2003).","journal-title":"Kidney Int"},{"key":"1408_CR21","first-page":"SA","volume":"18","author":"S Rowlinson","year":"2007","unstructured":"Rowlinson, S. et al. An anti-TGF-\u03b21 specific mAb demonstrates renal efficacy equivalent to a pan neutralizing mAb in the rat anti-Thy1.1 and mouse db\/db models. J. Am. Soc. Nephrol. 18, SA\u2013PO329 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1408_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaj1738","volume":"2","author":"G Gabriely","year":"2017","unstructured":"Gabriely, G. et al. Targeting latency-associated peptide promotes antitumor immunity. Sci. Immunol. 2, eaaj1738 (2017).","journal-title":"Sci. Immunol."},{"key":"1408_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adn6052","volume":"17","author":"JW Jackson","year":"2024","unstructured":"Jackson, J. W. et al. An antibody that inhibits TGF-beta1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. Sci. Signal 17, eadn6052 (2024).","journal-title":"Sci. Signal"},{"key":"1408_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni, A. B. et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90, 770\u2013774 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1408_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1083\/jcb.200611044","volume":"176","author":"Z Yang","year":"2007","unstructured":"Yang, Z. et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J. Cell Biol. 176, 787\u2013793 (2007).","journal-title":"J. Cell Biol."},{"key":"1408_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse, A. N., LaPorte, K. M. & Malek, T. R. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity 57, 414\u2013428 (2024).","journal-title":"Immunity"},{"key":"1408_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David, C. J. & Massague, J. Contextual determinants of TGFbeta action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419\u2013435 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1408_CR28","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1182\/blood-2008-04-151753","volume":"112","author":"J Ahamed","year":"2008","unstructured":"Ahamed, J. et al. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood 112, 3650\u20133660 (2008).","journal-title":"Blood"},{"key":"1408_CR29","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/gast.2001.24832","volume":"120","author":"M Okuno","year":"2001","unstructured":"Okuno, M. et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 120, 1784\u20131800 (2001).","journal-title":"Gastroenterology"},{"key":"1408_CR30","first-page":"1077","volume":"10","author":"MH Barcellos-Hoff","year":"1996","unstructured":"Barcellos-Hoff, M. H. & Dix, T. A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 10, 1077\u20131083 (1996).","journal-title":"Mol. Endocrinol."},{"key":"1408_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.biocel.2007.11.026","volume":"40","author":"G Jenkins","year":"2008","unstructured":"Jenkins, G. The role of proteases in transforming growth factor-beta activation. Int J. Biochem Cell Biol. 40, 1068\u20131078 (2008).","journal-title":"Int J. Biochem Cell Biol."},{"key":"1408_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Latent TGF-beta structure and activation. Nature 474, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"1408_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1091\/mbc.e11-12-1018","volume":"23","author":"R Wang","year":"2012","unstructured":"Wang, R. et al. GARP regulates the bioavailability and activation of TGFb. eta. Mol. Biol. Cell 23, 1129\u20131139 (2012).","journal-title":"eta. Mol. Biol. Cell"},{"key":"1408_CR34","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cancers11091221","volume":"11","author":"NF Brown","year":"2019","unstructured":"Brown, N. F. & Marshall, J. F. Integrin-mediated TGFbeta activation modulates the tumour microenvironment. Cancers (Basel) 11, 1221 (2019).","journal-title":"Cancers (Basel)"},{"key":"1408_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/nsmb.2905","volume":"21","author":"X Dong","year":"2014","unstructured":"Dong, X., Hudson, N. E., Lu, C. & Springer, T. A. Structural determinants of integrin beta-subunit specificity for latent TGF-beta. Nat. Struct. Mol. Biol. 21, 1091\u20131096 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1408_CR36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/sj.jid.5700331","volume":"126","author":"Y Asano","year":"2006","unstructured":"Asano, Y., Ihn, H., Jinnin, M., Mimura, Y. & Tamaki, K. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J. Invest Dermatol 126, 1761\u20131769 (2006).","journal-title":"J. Invest Dermatol"},{"key":"1408_CR37","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","volume":"175","author":"Y Asano","year":"2005","unstructured":"Asano, Y. et al. Increased expression of integrin \u03b1v\u03b23 contributes to the establishment of autocrine TGF-\u03b2 signaling in scleroderma fibroblasts1.  J. Immunol. 175, 7708\u20137718 (2005).","journal-title":"J. Immunol."},{"key":"1408_CR38","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1242\/jcs.070672","volume":"123","author":"S Liu","year":"2010","unstructured":"Liu, S. et al. Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J. Cell Sci. 123, 3674\u20133682 (2010).","journal-title":"J. Cell Sci."},{"key":"1408_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1242\/jcs.035246","volume":"122","author":"P Aluwihare","year":"2009","unstructured":"Aluwihare, P. et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 122, 227\u2013232 (2009).","journal-title":"J. Cell Sci."},{"key":"1408_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1083\/jcb.133.4.921","volume":"133","author":"XZ Huang","year":"1996","unstructured":"Huang, X. Z. et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J. Cell Biol. 133, 921\u2013928 (1996).","journal-title":"J. Cell Biol."},{"key":"1408_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1165\/rcmb.2006-0428OC","volume":"37","author":"LL Koth","year":"2007","unstructured":"Koth, L. L. et al. Integrin beta6 mediates phospholipid and collectin homeostasis by activation of latent TGF-beta1. Am. J. Respir. Cell Mol. Biol. 37, 651\u2013659 (2007).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1408_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature01413","volume":"422","author":"DG Morris","year":"2003","unstructured":"Morris, D. G. et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 422, 169\u2013173 (2003).","journal-title":"Nature"},{"key":"1408_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","volume":"206","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. A phase IIb randomized clinical study of an anti-\u03b1v\u03b26 monoclonal antibody in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 206, 1128\u20131139 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1408_CR44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/19420862.2017.1314873","volume":"9","author":"A Maeda","year":"2017","unstructured":"Maeda, A. et al. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs 9, 844\u2013853 (2017).","journal-title":"MAbs"},{"key":"1408_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D. Biol. Crystallogr 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Xds. Acta Crystallogr D. Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR47","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr D. Biol. Crystallogr 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D. Biol. Crystallogr 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR49","unstructured":"Tickle, I. J. et al. Staraniso. Global Phasing Ltd. (2016)."},{"key":"1408_CR50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"1408_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1408_CR53","unstructured":"Bricogne, G. B. E. et al. Buster version 2.11.7. Global Phasing Ltd. (2017)."},{"key":"1408_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"1408_CR55","doi-asserted-by":"publisher","first-page":"e0265081","DOI":"10.1371\/journal.pone.0265081","volume":"17","author":"M Iida","year":"2022","unstructured":"Iida, M. et al. TNF-alpha induces Claudin-1 expression in renal tubules in Alport mice. PLoS One 17, e0265081 (2022).","journal-title":"PLoS One"},{"key":"1408_CR56","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.omtn.2020.01.002","volume":"19","author":"H Ding","year":"2020","unstructured":"Ding, H., Xu, Y. & Jiang, N. Upregulation of miR-101a suppresses chronic renal fibrosis by regulating KDM3A via blockade of the YAP-TGF-beta-smad signaling pathway. Mol. Ther. Nucleic Acids 19, 1276\u20131289 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1408_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J. Exp. Pathol. 94, 93\u2013103 (2013).","journal-title":"Int J. Exp. Pathol."},{"key":"1408_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/10245332.2016.1232546","volume":"22","author":"M Pamukcuoglu","year":"2017","unstructured":"Pamukcuoglu, M. et al. Peripheral and bone marrow CD34(+) cell levels on chronic myeloproliferative disease. Hematology 22, 74\u201380 (2017).","journal-title":"Hematology"},{"key":"1408_CR59","doi-asserted-by":"publisher","first-page":"17029","DOI":"10.1074\/jbc.M110.110288","volume":"285","author":"KL Walton","year":"2010","unstructured":"Walton, K. L. et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J. Biol. Chem. 285, 17029\u201317037 (2010).","journal-title":"J. Biol. Chem."},{"key":"1408_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/01.ASN.0000042168.43665.9B","volume":"14","author":"H Ling","year":"2003","unstructured":"Ling, H. et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J. Am. Soc. Nephrol. 14, 377\u2013388 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1408_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s10020-022-00508-2","volume":"28","author":"X Song","year":"2022","unstructured":"Song, X. et al. Recombinant truncated latency-associated peptide alleviates liver fibrosis in vitro and in vivo via inhibition of TGF-beta\/Smad pathway. Mol. Med 28, 80 (2022).","journal-title":"Mol. Med"},{"key":"1408_CR62","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/bloodadvances.2017010868","volume":"2","author":"S Ghafoory","year":"2018","unstructured":"Ghafoory, S. et al. Platelet TGF-beta1 deficiency decreases liver fibrosis in a mouse model of liver injury. Blood Adv. 2, 470\u2013480 (2018).","journal-title":"Blood Adv."},{"key":"1408_CR63","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","volume":"17","author":"S Dennler","year":"1998","unstructured":"Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091\u20133100 (1998).","journal-title":"EMBO J."},{"key":"1408_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/biom9040141","volume":"9","author":"E Martinez-Klimova","year":"2019","unstructured":"Martinez-Klimova, E., Aparicio-Trejo, O. E., Tapia, E. & Pedraza-Chaverri, J. Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments. Biomolecules 9, 141 (2019).","journal-title":"Biomolecules"},{"key":"1408_CR65","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","volume":"10","author":"D Cosgrove","year":"1996","unstructured":"Cosgrove, D. et al. Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev. 10, 2981\u20132992 (1996).","journal-title":"Genes Dev."},{"key":"1408_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19920-5","volume":"11","author":"AL Grauel","year":"2020","unstructured":"Grauel, A. L. et al. TGFbeta-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nat. Commun. 11, 6315 (2020).","journal-title":"Nat. Commun."},{"key":"1408_CR67","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med 18, 1028\u20131040 (2012).","journal-title":"Nat. Med"},{"key":"1408_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature21035","volume":"542","author":"X Dong","year":"2017","unstructured":"Dong, X. et al. Force interacts with macromolecular structure in activation of TGF-beta. Nature 542, 55\u201359 (2017).","journal-title":"Nature"},{"key":"1408_CR69","doi-asserted-by":"crossref","unstructured":"Campbell, M. G. et al. Cryo-EM reveals integrin-mediated TGF-beta activation without release from latent TGF-beta. Cell 180, 490\u2013501.e416 (2020).","DOI":"10.1016\/j.cell.2019.12.030"},{"key":"1408_CR70","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jhep.2023.05.043","volume":"79","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. GARP on hepatic stellate cells is essential for the development of liver fibrosis. J. Hepatol. 79, 1214\u20131225 (2023).","journal-title":"J. Hepatol."},{"key":"1408_CR71","doi-asserted-by":"publisher","first-page":"H655","DOI":"10.1152\/ajpheart.00559.2023","volume":"326","author":"C Dufeys","year":"2024","unstructured":"Dufeys, C., Bodart, J., Bertrand, L., Beauloye, C. & Horman, S. Fibroblasts and platelets: a face-to-face dialogue at the heart of cardiac fibrosis. Am. J. Physiol. Heart Circ. Physiol. 326, H655\u2013H669 (2024).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1408_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109309","volume":"36","author":"E Dodagatta-Marri","year":"2021","unstructured":"Dodagatta-Marri, E. et al. Integrin alphavbeta8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 36, 109309 (2021).","journal-title":"Cell Rep."},{"key":"1408_CR73","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122591","volume":"3","author":"N Takasaka","year":"2018","unstructured":"Takasaka, N. et al. Integrin \u03b1v\u03b28-expressing tumor cells evade host immunity by regulating TGF-\u03b2 activation in immune cells. JCI Insight 3, e122591 (2018).","journal-title":"JCI Insight"},{"key":"1408_CR74","unstructured":"Kanamori, M. Cross-species anti-latent tgf-beta 1 antibodies and methods of use International Patent Application WO2021\/039945 (2021)."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01408-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:19:33Z","timestamp":1772461173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01408-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K., I.S., H.K., K.N, A.M, K.A., Y.S\n                      2\n                      ., M.S.-K., C.K., Y.K., N.H., K.O., T.K., T.I., and H.S. are employees of Chugai Pharmaceutical Co. Ltd. (Chugai). Y.S\n                      1\n                      ., and S.W.G. are employees of Chugai\u2019s subsidiary, Chugai Pharmabody Research Pte. Ltd.(Chugai Pharmabody Research). J.N was employees of Chugai, and C.X.K and C.L.P. were employees of Chugai Pharmabody Research at the time of the study. H.S. was a Chief Executive Officer of Chugai Pharmabody Research Pte. Ltd. M.K., I.S., H.K., K.N., A.M., K.A., Y.S\n                      2\n                      ., M.S.-K., C.K., Y.K., N.H., K.O., J.N., T.K., T.I., and H.S. have stock in Chugai. Chugai has filed patent applications related to the anti-latent TGF-\u03b21 antibodies. M.K. is the inventor of the following patent: CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE (WO2019\/163927). M.K., H.S., and C.X.K. are the inventors of the following patent: CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE (WO2021\/039945) and USES OF CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES (WO2022\/180764).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}